

November 27, 2019

The Manger - Listing

**BSE Limited**

Corporate Relationship Dept., 1<sup>st</sup> Floor, New Trading Ring  
Rotunda Building, P J Towers, Dalal Street, Fort,  
Mumbai 400001

**National Stock Exchange of India Ltd.**

Exchange plaza, 5<sup>th</sup> Floor, Plot No.C/1, G Block  
Bandra-Kurla Complex, Bandra (E),  
Mumbai 400051

Dear Sir(s),

**Sub: Disclosure of Related Party Transactions**

**Ref: Scrip Code – BSE: 506820, NSE: ASTRAZEN**

Pursuant to the provisions of Regulation 23 (9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, we enclose herewith the disclosure of Related Party Transactions for half year ended September 30, 2019 for your information and records.

For AstraZeneca Pharma India limited



Pratap Rudra

Company Secretary & Legal Counsel



**AstraZeneca Pharma India Limited**

**Disclosure of related party transactions for the half year ended 30 September, 2019**

**In pursuance with Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) (Amendments) Regulations, 2018**

(All amounts in Rs.million, except per share and share data)

**(i) Names of related parties and related party relationship**

**(a) Related parties where control exists and/or where transactions have occurred:**

| <u>Name of the entity</u>                                                  | <u>Name of relationship</u>                                                                                                                                                                                                           |
|----------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Holding Company                                                            | AstraZeneca Pharmaceuticals AB, Sweden                                                                                                                                                                                                |
| Holding Company of AstraZeneca Pharmaceuticals AB, Sweden                  | AstraZeneca AB, Sweden                                                                                                                                                                                                                |
| Holding Company of AstraZeneca AB, Sweden                                  | AstraZeneca Treasury Limited, United Kingdom                                                                                                                                                                                          |
| Ultimate Holding Company                                                   | AstraZeneca Plc, United Kingdom                                                                                                                                                                                                       |
| Fellow subsidiaries with whom the company had transactions during the year | AstraZeneca Singapore Pte Ltd, Singapore<br>AstraZeneca India Private Limited, India<br>AstraZeneca Pharmaceuticals LP, USA<br>AstraZeneca UK Limited, United Kingdom<br>P.T. AstraZeneca Indonesia<br>AstraZeneca Pty Ltd, Australia |
| Employees' Benefit Plans                                                   | AstraZeneca Pharma India Limited Employees Gratuity Fund Trust<br>AstraZeneca Pharma India Limited Management Staff Provident Fund Trust<br>AstraZeneca Pharma India Limited Management Staff Superannuation Fund Trust               |

**b) Key Management Personnel**

|                                        |                                               |
|----------------------------------------|-----------------------------------------------|
| - Managing Director                    | Mr. Gagandeep Singh Bedi                      |
| - Director and Chief Financial Officer | Mr. Rajesh Marwaha                            |
| - Non-Executive Directors              | Mr. Ian John Parish<br>Ms. Weiyang Sarah Wang |

**c) Independent Directors**

Mr. Narayan K Seshadri  
Ms. Revathy Ashok  
Ms. Kimsuka Narasimhan



**AstraZeneca Pharma India Limited**

Disclosure of related party transactions for the half year ended 30 September, 2019

**In pursuance with Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) (Amendments) Regulations, 2018**

(All amounts in Rs.million, except per share and share data)

(ii) Details of the transactions with the related parties during the period 01 April 2019 to 30 September 2019 :

|                                                                             |         |
|-----------------------------------------------------------------------------|---------|
| <b>Purchase of materials and traded goods</b>                               |         |
| AstraZeneca UK Limited, United Kingdom                                      | 1,220.1 |
| AstraZeneca AB, Sweden                                                      | 103.2   |
| <b>Payment towards reimbursement of expenses</b>                            |         |
| AstraZeneca UK Limited, United Kingdom                                      | 8.2     |
| AstraZeneca Pty Ltd, Australia                                              | 2.0     |
| <b>Sale of services</b>                                                     |         |
| AstraZeneca AB, Sweden                                                      | 187.0   |
| <b>Recovery of reimbursable expenses</b>                                    |         |
| AstraZeneca UK Limited, United Kingdom                                      | 29.8    |
| AstraZeneca AB, Sweden                                                      | 33.7    |
| P.T. AstraZeneca Indonesia                                                  | 14.6    |
| AstraZeneca Singapore Pte Ltd, Singapore                                    | 4.6     |
| AstraZeneca Pharmaceuticals LP, USA                                         | 6.6     |
| <b>Contribution to Trusts</b>                                               |         |
| AstraZeneca Pharma India Limited Management Staff Superannuation Fund Trust | 6.3     |

(iii) (a) Transactions with Key Management Personnel

|                                      |             |
|--------------------------------------|-------------|
| <b>Salary and perquisites</b>        |             |
| Short-term employee benefits         | 37.6        |
| Long-term employee benefits          | 7.4         |
| Post employment benefits             | 15.1        |
| Employee share compensation expenses | 2.3         |
|                                      | <b>62.3</b> |

(iii) (b) Transactions with Independent Directors

|                                            |     |
|--------------------------------------------|-----|
| Sitting fees paid to independent directors | 1.7 |
|--------------------------------------------|-----|

(iv) Details of balances receivable from and payable to related parties as at 30 September, 2019 are as follows:

|                                          |              |
|------------------------------------------|--------------|
| <b>Other current financial assets</b>    | <b>35.5</b>  |
| AstraZeneca UK Limited, United Kingdom   | 28.0         |
| AstraZeneca Pharmaceuticals LP, USA      | 2.8          |
| AstraZeneca Singapore Pte Ltd, Singapore | 2.1          |
| P.T. AstraZeneca Indonesia               | 2.7          |
| <b>Trade receivables</b>                 | <b>121.1</b> |
| AstraZeneca AB, Sweden                   | 121.1        |
| <b>Trade payables</b>                    | <b>690.9</b> |
| AstraZeneca UK Limited, United Kingdom   | 614.4        |
| AstraZeneca AB, Sweden                   | 74.5         |
| AstraZeneca Pty Ltd, Australia           | 2.0          |

